Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

LY294002

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

PI3K inhibitor, AKT inhibitor, FAK inhibitor

Related drugs:

‹

FAK-JAK 2 dual Inhib (0)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

enzastaurin (3)

BAY 1082439 (1)

capivasertib (35)

pexidartinib (6)

antroquinonol (0)

FAK-JAK 2 dual Inhib (0)

›

KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
TP53 mutation	Colorectal Cancer	TP53 mutation	Colorectal Cancer	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
MTOR H1968Y	Melanoma	MTOR H1968Y	Melanoma	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
MTOR P2213S	Melanoma	MTOR P2213S	Melanoma	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
MTOR S2215Y	Melanoma	MTOR S2215Y	Melanoma	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D